Now accepting Telehealth appointments. Schedule a virtual visit.

A new clinical trial at CHR for women who need growth hormone: Rx Semorelin

A new clinical trial at CHR for women who need growth hormone: Rx Semorelin

Human growth hormone (HGH) has over the last decade returned to popularity in IVF cycles and is increasingly utilized at many IVF centers, including at CHR. The costs of HGH for patients are, however, significant, especially if used correctly, which here at CHR is believed to mean that supplementation must be initiated at least 6-8 weeks before IVF cycle start and through the IVF cycle itself. Moreover, insurance companies usually do not cover HGH use in IVF since they consider it experimental treatment, which CHR in most cases agrees with.

To potentially safe patients thousands of dollars, CHR is announcing a preliminary trial of a drug called Semorelin, which releases endogenous HGH from the pituitary.

The purpose of the first phase of this study is to determine whether Semorelin does so effectively enough to replace administration of HGH and at what dosage. Since Semorelin is a much less expensive medication. It would safe patients thousands of dollars in every IVF cycle if this switch could be accomplished. CHR will cover the costs of Semorelin during the study period.

HGH is not an active biological agent; it works through a substance called insulin-like growth factor – 1 (IGF-1) which is mostly produced in the liver but also in ovaries and elsewhere. The study will, therefore, compare whether Semorelin produces similar IGF-1 levels as HGH administration achieves.

If you are interested in this study, please contact CHR by calling 1-212-994-4400 and make an appointment for an initial consultation with one of our physicians.

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    

 


We have helped women bring over
17,800 babies into the world.

DISCOVER YOUR TREATMENT OPTIONS

 

You Might Also Enjoy...

The May Voice

As always, we are delighted to welcome all of our readers to a new issue of The CHR VOICE. Our May issue is again made up of a compendium of articles that will hopefully satisfy the broad spectrum of our readership, made up of current and past CHR patients

The April Voice

We very enthusiastically welcome you to the April issue of The CHR VOICE because, over the last month, we had the opportunity to put together our most expansive issue so far (44 pages).

March VOICE

We welcome all of our readers to the March issue of The CHR VOICE, which, as usual, in the new and expanded format offers a broad potpourri of articles for patients and laypeople as well as professional physicians and scientists working in reproductive med

The Voice February 2023

We are very pleased to offer the February 2023 issue of THE CHR VOICE and want to take the opportunity of this introduction to direct the attention of our readers...